Fig. 1
From: Saliva-based lacosamide monitoring paves the way toward personalized epilepsy pharmacotherapy
Analysis of lacosamide Levels in blood and saliva in relation to dosage and genotype. (A, B) The linear correlation was shown between BSA-normalized daily dose of lacosamide (mg/m2/day) and its concentration in (A) blood (n = 86) and (B) saliva (n = 109), respectively. (C) A linear regression model described the relationship between blood and saliva lacosamide levels (n = 74) (Csaliva = 4.932 + 0.652 × Cblood, adjusted R2 = 0.38). (D, E) Boxplots represent the dose-normalized (D) blood (n = 146) and (E) saliva (n = 37) levels of lacosamide across three CYP2C19 genotype group, respectively, with significance determined using the Jonckheere-Terpstra test (blood level: P < 0.001, saliva level: P = 0.029). Dose normalization was calculated as concentration × 300 mg/day/daily dose (mg/day). Data in blood sample were merged with the previous study (Supplementary Table 1). BSA body surface area.
